Tevogen Bio Holdings Inc. 8-K

What Happened
Tevogen Bio Holdings Inc. reported in an 8-K filed March 25, 2026 that on March 20, 2026 it received a written notice from The Nasdaq Stock Market LLC confirming the company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1) for continued listing on the Nasdaq Global Market. The Notification Letter followed the company’s 1-for-50 reverse stock split, which became effective March 6, 2026, and Nasdaq indicated the matter is now closed.

Key Details

• Notification date from Nasdaq: March 20, 2026.
• Nasdaq rule satisfied: Listing Rule 5450(a)(1) (minimum bid price).
• Reverse split implemented: 1-for-50, effective March 6, 2026.
• Related filing: Company’s Form 8-K on March 4, 2026 described the Reverse Split.

Why It Matters
Regaining compliance means Tevogen remains listed on the Nasdaq Global Market and is not subject to delisting procedures related to minimum bid price at this time—preserving investors’ ability to trade the stock on Nasdaq. The reverse stock split is an administrative action to raise the per‑share trading price to meet exchange requirements; it consolidates outstanding shares but does not itself change the company’s underlying business operations.